VHT vs XBI
Vanguard Health Care ETF vs SPDR S&P Biotech ETF
- • VHT has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VHT pays a higher dividend yield (1.72%).
Side-by-side metrics
| Metric | VHT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.72% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $18.51B | $8.30B |
YTD return | -4.77% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.64 | 1.09 |
P/E ratio | 25.44 | — |
Last price | $271.09 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VHT top holdings
| LLY | Eli Lilly and Co | 11.89% |
| JNJ | Johnson & Johnson | 9.34% |
| ABBV | AbbVie Inc | 6.18% |
| MRK | Merck & Co Inc | 4.80% |
| UNH | UnitedHealth Group Inc | 3.94% |
| AMGN | Amgen Inc | 3.05% |
| TMO | Thermo Fisher Scientific Inc | 2.97% |
| ABT | Abbott Laboratories | 2.87% |
| GILD | Gilead Sciences Inc | 2.78% |
| ISRG | Intuitive Surgical Inc | 2.63% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VHT
VHT (Vanguard Health Care ETF) is US health care sector stocks. Managed by Vanguard, the fund carries $18.5B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.72%. Its largest holding is Eli Lilly and Co (LLY), which represents 11.9% of the portfolio. Technology is the fund's largest sector exposure at 0.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.